EUVIMEDEUVIMED entdecken
Crossref

Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease

Nicole C Reyna iD, Derek A Hamilton iD

Hippocampus · 2026-05 · 36 (3)

DOI: 10.1002/hipo.70103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hippocampus, online erschienen am 20.05.2026. Verfasst von Nicole C Reyna und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University of New Mexico, Albuquerque, New Mexico, USA. Hauptthemen laut MEDLINE: Dentate Gyrus, Long-Term Potentiation, Alzheimer Disease, Receptors, Corticotropin-Releasing Hormone. Die Arbeit nennt 74 Literaturangaben. Gefördert von: NIA NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is characterized by irreversible neurobiological deterioration and cognitive impairment. AD patients exhibit stress system abnormalities including upregulation of the corticotropin releasing factor type 1 receptor (CRF 1 ) and elevated cortisol. Psychological distress increases the likelihood of AD diagnosis and hastens neurocognitive decline. Administration of the CRF 1 antagonist, Antalarmin, reduces AD pathogenesis and anxiety‐like behavior in models of AD. Motivated by these observations, the current study examined the potential contributions of CRF 1 to altered synaptic plasticity in AD neuropathology and stress in the TgF344‐AD rat model. In vivo electrophysiological recordings to assess long‐term potentiation (LTP) in the perforant pathway to dentate gyrus synapses were performed in aged transgenic rats and wild‐type (WT) controls (2–2.5 years). TgF344‐AD rats had abnormal LTP measures of field excitatory post‐synaptic potentials (fEPSP) and population spikes (PS). Treatment with Antalarmin did not alter LTP measures in TgF344‐AD or WT rats. These observations indicate that LTP in TgF344‐AD rats is reduced compared to WT rats and that acute treatment with a CRF 1 antagonist did not rescue LTP deficits. Future research should further examine the mechanism of CRF 1 in AD and implications of agonism or direct infusions of Antalarmin in vivo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dentate GyrusLong-Term PotentiationAlzheimer DiseaseReceptors, Corticotropin-Releasing HormonePyrimidinesPyrrolesAnimalsDisease Models, AnimalCRF Receptor, Type 1Rats, TransgenicMaleRatsRats, Inbred F344Excitatory Postsynaptic PotentialsPerforant Pathway

Stichwörter der Autor:innen

Alzheimer's diseasecorticotropin‐releasing factor 1 antagonismdentate gyrusin vivo electrophysiologylong‐term potentiation

Substanzen

Receptors, Corticotropin-Releasing HormonePyrimidinesCRF Receptor, Type 1antalarminPyrroles

Autor:innen und Institutionen

  • Department of Psychology, University of New Mexico, Albuquerque, New Mexico, USA.

ORCID-Profile: Nicole C Reyna, Derek A Hamilton

Förderung

  • NIA NIH HHS
  • National Institute on Aging

Zitieren

APA

Reyna, N. C., & Hamilton, D. A. (2026). Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease. Hippocampus, 36(3). https://doi.org/10.1002/hipo.70103

Vancouver

Reyna NC, Hamilton DA. Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease. Hippocampus. 2026;36(3). doi:10.1002/hipo.70103

BibTeX
@article{Reyna2026,
  author = {Reyna, Nicole C and Hamilton, Derek A},
  title = {Effects of Corticotropin‐Releasing Factor 1 Receptor Antagonism on In Vivo Dentate Gyrus Long‐Term Potentiation in the TgF344 ‐ AD Rat Model of Alzheimer's Disease},
  journal = {Hippocampus},
  year = {2026},
  volume = {36},
  number = {3},
  doi = {10.1002/hipo.70103}
}
Kostenlos starten →